Concerted overexpression of the genes encoding p21 and cyclin D1 is associated with growth inhibition and differentiation in various carcinomas

Journal of Clinical Pathology - Molecular Pathology

Volumn 52, Issue 2, 1999, Pages 78-83

  De Jong, J S ^a   Van Diest, P J ^a   Michalides, R J A M ^b   Baak, J P A ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Cyclin D1; Differentiation; P21; Proliferation

Indexed keywords

CYCLIN D1; PROTEIN P21;

ARTICLE; BREAST CANCER; CANCER GENETICS; CANCER GROWTH; CANCER INHIBITION; CELL STRAIN MCF 7; CYSTADENOCARCINOMA; GENE OVEREXPRESSION; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; OVARY ADENOCARCINOMA; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TUMOR DIFFERENTIATION;

EID: 0032951329     PISSN: 13668714     EISSN: None     Source Type: Journal    
DOI: 10.1136/mp.52.2.78     Document Type: Article

References (54)

1. Koff A, Giordano A, Desai D, et al. Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle. Science 1992;257:1689-94.
2. Lew DJ, Dulic V, Reed SI. Isolation of three novel human cyclins by rescue of G1 cyclin (Cln) function in yeast. Cell 1991;66:1197-206.
3. Rosenberg AR, Zindy F, Le Deist F, et al. Overexpression of human cyclin A advances entry into S phase. Oncogene 1995;10:1501-9.
4. Nurse P. Universal control mechanism regulating onset of M-phase. Nature 1992;344:503-8.
5. Sherr CJ. Mammalian G1 cyclins. Cell 1993;73:1059-65.
6. Grana X, Reddy EP. Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene 1995;11:211-19.
7. WAF1/CIP1 expression by p53-independent pathways. Oncogene 1996;12:1557-64.
8. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993;366:704-7.
9. El-Diery WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-25.
10. Toyoshima H, Hunter T. p27, a novel inhibitor of G1 cyclin-cdk protein kinase activity, is related to p21. Cell 1994;78:67-74.
11. Matsuoka S, Edwards MC, Bai C, et al. p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev 1995;9:650-62.
12. El-Diery WS, Harper JW, O'Conner PM, et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 1994;54:1169-74.
13. Zhang H, Hannon GJ, Beach D. p21-containing cyclin kinases exist in both active and inactive states. Genes Dev 1994;8:1750-8.
14. Xiong Y, Hannon GJ, Zhang H, et al. p21 is a universal inhibitor of cyclin kinases. Nature 1993;366:701-4.
15. Yang ZY, Perkins ND, Ohno T, et al. The p21 cyclin-dependent kinase inhibitor suppresses tumorigenicity in vivo. Nat Med 1995;1:1052-6.
16. Quelle DE, Ashmun RA, Shurtleff SA, et al. Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts. Genes Dev 1993;7:1559-71.
17. Resnitzky D, Reed SI. Different roles for cyclin D1 and E in regulation of the G1-to-S transition. Mol Cell Biol 1995;15: 3463-9.
18. Musgrove EA, Lee SCL, Buckley MF, et al. Cyclin D1 induction in breast cancer cells shortens G1 and is sufficient for cells arrested in G1 to complete the cell cycle. Proc Natl Acad Sci USA 1994;91:8022-6.
19. Landberg G, Nielsen NH, Nilsson P, et al. Telomerase activity is associated with cell cycle deregulation in human breast cancer. Cancer Res 1997;57:549-54.
20. Han EK-H, Sgambato A, Jiang W, et al. Stable overexpression of cyclin D1 in a human mammary epithelial cell line prolongs the S-phase and inhibits growth. Oncogene 1995;10:953-61.
21. Pagano M, Theodoras AM, Tam SW, et al. Cyclin D1-mediated inhibition of repair and replicative DNA synthesis in human fibroblasts. Genes Dev 1994;8:1627-39.
22. Diest van PJ, Michalides RJAM, Jannink I, et al. Cyclin D1 expression in invasive breast cancer: correlations and prognostic value. Am J Pathol 1997;150:705-11.
23. Gillett C, Smith P, Gregory W, et al. Cyclin D1 and prognosis in human breast cancer. Int J Cancer 1996;69:292-9.
24. Michalides R, Hageman PH, van Tinteren H, et al. A clinico-pathological study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer. Br J Cancer 1996;73:728-34.
25. Barbareschi M, Pelosio P, Caffo O, et al. Cyclin-D1 gene amplification and expression in breast carcinoma: relation with clinicopathologic characteristics and with retinoblastoma gene product, p53 and p21 WAF1 immunohistochemical expression. Int J Cancer 1997;74:171-4.
26. Lammie GA, Peters G. Chromosome 11q13 abnormalities in human cancer. Cancer Cells 1991;3:413-20.
27. Motokura T, Arnold A. Cyclins and oncogenesis. Biochem Biophys Acta 1993;1155:63-78.
28. Hall M, Peters G. Genetic alterations of cyclins, cyclin-dependent kinases and Cdk inhibitors in human cancer. Adv Cancer Res 1996;68:67-108.
29. Motokura T, Bloom T, Kim HG, et al. A novel cyclin encoded by a bc11-linked candidate ongogene. Nature 1991;350:512-5.
30. Boer de CJ, Krieken JHJM, Nelemans HCK, et al. Cyclin D1 messenger RNA overexpression as a marker for mantle cell lymphoma. Oncogene 1995;10:1833-40.
31. Rosenberg CL, Wong E, Petty EM, et al. PRAD1, a candidate BCL-1 oncogene: mapping and expression in centrocytic lymphoma. Proc Natl Acad Sci USA 1991;88:9638-42.
32. Withers DA, Harvey RC, Faust JB, et al. Characterization of a candidate BCL-1 gene. Mol Cell Biol 1991;11:4846-53.
33. Bobrow MN, Litt GJ. The use of catalyzed reporter deposition as a means of signal amplification in a variety of formats. J Immunol Methods 1992;150:145-9.
34. Zwijssen RM, Klompmakers R, Wientjes EB, et al. Cyclin D1 triggers autonomous growth of breast cancer cells by governing cell cycle exit. Mol Cell Biol 1991;16:2554-60.
35. Lowry OH, Rosebrough NJ, Farr AL, et al. Protein measurement with the folin phenol reagent. J Biol Chem 1995;193:265-75.
36. Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA 1992;89:5547-51.
37. Lukas J, Bartkova J, Bartek J. Convergence of mitogenic signaling cascades from diverse classes of receptors at the cyclin D-cyclin dependent-kinase-pRb-controlled G1 checkpoint. Mol Cell Biol 1996;16:6917-25.
38. Wang TC, Cardiff RD, Zukerberg L, et al. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 1994;369:669-71.
39. Robles AI, Larcher F, Whalin RB, et al. Expression of cyclin D1 in epithelial tissues of transgenic mice results in epidermal hyperproliferation and severe thymic hyperplasia. Proc Natl Acad Sci USA 1996;93:7634-8.
40. 1 regulation in human head and neck cancer. Cancer Res 1995;55:949-56.
41. Uhlman DL, Adams G, Knapp D, et al. Immunohistochemical staining for markers of future neoplastic progression in the larynx. Cancer Res 1996;56:2199-205.
42. Doglioni C, Pelosio P, Laurino L, et al. p21/WAF1/CIP1 expression in normal mucosa and in adenomas and adenocarcinomas of the colon: its relationship with differentiation. J Pathol 1996;179:248-53.
43. Marchetti A, Doglioni C, Barbareschi M, et al. p21 RNA and protein expression in non-small cell lung carcinomas: evidence of p53-independent expression and association with tumoral differentiation. Oncogene 1996;12:1319-24.
44. Poluha W, Poluha DK, Chang B, et al. The cyclin-dependent kinase inhibitor p21 (WAF1) is required for survival of differentiating neuroblastoma cells. Mol Cell Biol 1996;16:1335-41.
45. Tron VA, Tang L, Yong WP, et al. Differentiation-associated overexpression of the cyclin-dependent kinase inhibitor p21 waf-1 in human cutaneous squamous cell carcinoma. Am J Pathol 1996;149:1139-16.
46. Hiyama H, Lavarone A, LaBaer J, et al. Regulated ectopic expression of cyclin D1 induces transcriptional activation of the cdk inhibitor p21 gene without altering cell cycle progression. Oncogene 1997;14:2533-42.
47. Winston JT, Pledger WJ. Growth factor regulation of cyclin D1 mRNA expression through protein synthesis-dependent and -independent mechanisms. Mol Biol Cell 1993;4:1133-44.
48. Sutherland RI, Hamilton JA, Sweeney KJ, et al. Expression and regulation of cyclin genes in breast cancer. Acta Oncol 1995;34:651-6.
49. Chen X, Bargonnetti J, Prives C. p53, through p21 (WAF1/CIP1), induces cyclin D1 synthesis. Cancer Res 1995;55:4257-63.
50. Guillot C, Falette N, Paperin MP, et al. p21 (WAF1/CIP1) response to genotoxic agents in wild-type TP53 expressing breast primary tumours. Oncogene 1997;14:45-52.
51. WAF1/CIP1 expression through mitogen-activated protein kinase signaling pathway. Cancer Res 1996;56:31-5.
52. CIP1 WAF1 protein accumulation in head-and-neck cancer. Int J Cancer 1997;74:383-9.
53. Michalides R, van Veelen N, Hart A, et al. Overexpression of cyclin D1 correlates with recurrence in a group of forty-seven operable squamous cell carcinomas of the head and neck. Cancer Res 1995;55:975-8.
54. Michalides R, van Veelen N, Kristel P, et al. Overexpressionof cyclin D1 indicates a poor prognosis in squamous cellcarcinoma of the head and neck. Arch Otolaryngol 1997;123:497-502.